Biom Therapeutics is one of Three Finalists in the Annual Florida BioPitch Competition

The Sarasota-based biopharmaceutical company bested 47 highly competitive peers in successfully pitching life sciences’ investors.

SARASOTA, FL - November 7, 2020 - Biom Therapeutics is one of three finalists in the annual BioFlorida Conference’s BioPitch competition, the voice of Florida’s life sciences industry. Biom joins an esteemed group of early-stage companies, successfully advancing from the previous semi-finalist round of twelve.

BioFlorida represents roughly 6,700 establishments and research organizations over a range of related sectors - health IT, medical technology, biopharmaceuticals, and bioagriculture. Close to 100,000 Floridians are employed by BioFlorida member organizations and their annual conference brings together key stakeholders from life science companies, research institutions, economic development agencies, investors, and medical centers.

“We are truly grateful for everyone who voted for Biom during the BioFlorida pitch competition,” remarked John Allen, President of Biom Therapeutics. Johnson and his team entered a competitive field of 50 well-respected, early-stage life sciences companies. Criteria for entry centered on companies developing products in any area of life sciences or healthcare, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare IT, healthcare services, and plant/animal sciences. This also included devices, vaccines, or therapeutics in the fight against COVID-19.

Biom Therapeutics is a Sarasota-based clinical-stage biopharmaceutical company founded by Mr. Allen and two colleagues. The company develops therapeutics for hard-to-treat neurological diseases with an initial focus on rare pediatric epilepsy, including developmental and epileptic encephalopathies and Angelman syndrome. Part of the process of arriving at the final round of the competition was successfully pitching an esteemed panel of investors from well-respected firms such as Florida Funders, HealthQuest Capital, New World Angels, and Capitala Group, among others.

“Being nominated as a top 3 finalist from this highly competitive pool of companies speaks to Biom’s compelling investment proposition, the importance of what we do, and the notable progress we’ve made,” added Allen. As a finalist, Biom is actively seeking seed and early-stage investment. The company counts on a state-of-the-art biomedical research facility and a dosage formulation lab to develop various forms of pharmaceutical-grade formulations.

###

About Biom Therapeutics

Biom Therapeutics is a biopharmaceutical company developing therapeutics for rare neurological childhood diseases. The company counts on partnerships with top pharmaceutical companies, federal and state agencies, and major epilepsy academic centers.